Robbin Mulina
Psychiatric/Mental Health · Houma, LANPI 1992154900
Payments from drug & device makers
Across 244 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$778
- AbbVie$742
- Otsuka America Pharmaceutical, Inc.$605
- Neurocrine Biosciences, Inc.$563
- Alkermes, Inc.$495
- Johnson & Johnson$434
- plus $1K from 12 others
What the payments were for
- Food & beverage$5,038100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$306
How this compares
$5,040 in reported general payments places this provider in the 85th percentile of 615 psychiatric/mental health providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 37 | $100,021 |
| Abilify MaintenaAripiprazole | 11 | $29,160 |
| VraylarCariprazine Hcl | 14 | $20,067 |
| Guanfacine Hcl ErGuanfacine Hcl | 26 | $553 |
| Haloperidol Decanoate | 13 | $471 |
| Quetiapine Fumarate | 32 | $265 |
| Mirtazapine | 17 | $235 |
| Divalproex Sodium ErDivalproex Sodium | 13 | $217 |
| Benztropine Mesylate | 16 | $216 |
| Aripiprazole | 13 | $180 |
| Buspirone Hcl | 23 | $164 |
| Escitalopram Oxalate | 27 | $146 |
| Hydroxyzine Hcl | 17 | $110 |
| Lamotrigine | 14 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $434 | $100,02137 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $605 | $29,16011 claims |
| AbbVieVraylar | $742 | $20,06714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Houma
- Amanda EymardHouma$617K
- Timothy PellegrinHouma$210K
- Harry BrownHouma$9K
- Amy LacoutureBaton Rouge$663K
- Amber LittlefieldBroussard$225K
- Melissa GuilbeauLafayette$122K
- Kimberly ForcinelShreveport$92K
- Sattaria DilksLake Charles$57K
- Joe TaylorHammond$38K
- Lecy AlbaradoScott$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.